In vitro activity of ceftriaxone and other cephalosporins against 602 clinical isolates of staphylococci from geographically diverse medical centers |
| |
| Authors: | M. A. Pfaller A. L. Barry L. D. Sabath B. N. Kreiswirth P. R. Murray P. C. Fuchs J. C. McLaughlin |
| |
| Affiliation: | (1) Clinical Pathology L471, Oregon Health Sciences University, 97201 Portland, Oregon, USA;(2) Clinical Microbiology Institute, Tualatin, Oregon;(3) University of Minnesota, Minneapolis, Minnesota;(4) Public Health Research Institute, New York, New York;(5) Barnes Hospital, St. Louis, Missouri;(6) St. Vincent Hospital & Medical Center, Portland, Oregon;(7) University of New Mexico Medical Center, Albuquerque, New Mexico;(8) Present address: Department of Pathology, University of Iowa College of Medicine, 273 MRC, 52242 Iowa City, Iowa |
| |
| Abstract: | ![]()
The in vitro activity of ceftriaxone and six additional antimicrobial agents (ceftizoxime, cefoperazone, cefuroxime, fleroxacin, ciprofloxacin, and trimethoprim/sulfamethoxazole) was assessed or 602 recent clinical isolates of staphylococci from six geographically distinct medical centers in North America. All seven antimicrobial agents were active (90–100% of strains susceptible) against oxacillin-susceptible (OS) strains of Staphylococcus aureus (OSSA) and coagulase-negative staphylococci (OSCNS) but had limited activity against oxacillin resistant (OR) staphylococci. Our assessment of the in vitro antistaphylococcal activity of ceftriaxone against contemporary isolates of Staphylococcus aureus and coagulase-negative staphylococci indicates that the activity versus OS staphylococci has not changed over the past decade despite widespread use of the drug. It appears that these agents will continue to be useful for empiric therapy in those centers in which OR strains are uncommon.Corresponding author. |
| |
| Keywords: | Ceftriaxone Cephalosporins Staphylococci |
| 本文献已被 SpringerLink 等数据库收录！ |
|
